• Nazli Gülsoy Kirnap, Özlem Turhan Iyidir, Yusuf Bozkuş, Şerife Mehlika Işildak, Cüneyd Anil, Sevde Nur Firat, Canan Demir, Asli Nar, and Neslihan Başçil Tütüncü.
• Department of Endocrinology and Metabolism, Faculty of Medicine, Başkent University, Ankara, Turkey
• Turk J Med Sci. 2020 Jun 23; 50 (4): 870-876.

Background/AimOvert thyroidism is known to cause neuropsychiatric disorders but studies on subclinical hyperthyroidism (SCH) are limited. Subclinical hyperthyroidism induction by administering L-Thyroxine (LT4) is the standard treatment method in differentiated thyroid carcinoma (DTC) follow-up. Our aim was to investigate whether anxiety, depression and quality of life are affected in DTC patients followed-up with exogenous SCH.Materials And MethodsThe patients were divided into exogenous SCH by LT4-DTC (n = 127), euthyroid-DTC (n = 66) and exogenous euthyroid-benign thyroid noduüle (BTN) who underwent thyroidectomy for benign thyroid pathology (n = 85) groups.ResultsThe rate of moderate/severe anxiety was significantly higher in SCH-DTC than euthyroid-BTN group (27.5%, n = 35 vs. 9.4%, n = 8) (P = 0.001). TSH levels and Beck anxiety inventory (BAI) scores were significantly negatively correlated(P = 0.009 r = –0.16). Free T4 and BAI were significantly positively correlated (P = 0.04 r = 0.4). The groups were similar in terms of depression severity (P = 0.15). Subclinical hyperthyroid-DTC group scored significantly lowerthan euthyroid-BTN group in all scales of SF-36 quality of life survey.ConclusionLT4-induced SCH, which is a part of traditional DTC treatment, can exacerbate the anxiety symptoms in patients and disrupt their quality of life, depending on the level of fT4.This work is licensed under a Creative Commons Attribution 4.0 International License.

24 keywords...

hide…